Monopar appoints Susan Rodriguez as Chief Commercial and Strategy Officer; NDA submission planned H1 2026

Monopar Therapeutics

Susan Rodriguez appointed Chief Commercial and Strategy Officer, effective March 2, 2026.
She will lead commercial strategy ahead of planned NDA submission for ALXN1840 (Wilson disease) in H1 2026.
Ms. Rodriguez previously was COO of Avadel, acquired by Alkermes for over $2 billion.
She also served as CCO of Ardelyx, establishing its first commercial organization and launching two therapies.
Over 30 years of biopharma leadership; holds MS/BS from University of Pennsylvania.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.